EUVIMEDEUVIMED entdecken
Open Access

Precision generalized phase I-II designs

Saijun Zhao, Peter F Thall, Ying Yuan iD, Juhee Lee iD, Pavlos Msaouel iD, Yong Zang iD

Biometrics · 2025

DOI: 10.1093/biomtc/ujaf043 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biometrics, 2025. Verfasst von Saijun Zhao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics and Health Data Science, School of Medicine, Indiana University, Indianapolis, IN 46202, USA. Hauptthemen laut MEDLINE: Clinical Trials, Phase II as Topic, Clinical Trials, Phase I as Topic, Research Design. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A new family of precision Bayesian dose optimization designs, PGen I-II, based on early efficacy, early toxicity, and long-term time to treatment failure is proposed. A PGen I-II design refines a Gen I-II design by accounting for patient heterogeneity characterized by subgroups that may be defined by prognostic levels, disease subtypes, or biomarker categories. The design makes subgroup-specific decisions, which may be to drop an unacceptably toxic or inefficacious dose, randomize patients among acceptable doses, or identify a best dose in terms of treatment success defined in terms of time to failure over long-term follow-up. A piecewise exponential distribution for failure time is assumed, including subgroup-specific effects of dose, response, and toxicity. Latent variables are used to adaptively cluster subgroups found to have similar dose-outcome distributions, with the model simplified to borrow strength between subgroups in the same cluster. Guidelines and user-friendly computer software for implementing the design are provided. A simulation study is reported that shows the PGen I-II design is superior to similarly structured designs that either assume patient homogeneity or conduct separate trials within subgroups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials, Phase II as TopicClinical Trials, Phase I as TopicResearch DesignHumansBayes TheoremComputer SimulationModels, StatisticalDose-Response Relationship, DrugBiometry

Stichwörter der Autor:innen

Bayesian adaptive designcell therapydose optimizationphase I-II clinical trialsprecision medicine

Autor:innen und Institutionen

  • Department of Biostatistics and Health Data Science, School of Medicine, Indiana University, Indianapolis, IN 46202, USA.
  • Department of Biostatistics, M.D. Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Statistics, University of California Santa Cruz, Santa Cruz, CA 95064, USA.
  • Departments of Genitourinary Medical Oncology and Translational Molecular Pathology, M.D. Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Biostatistics and Health Data Science, Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.

ORCID-Profile: Ying Yuan, Juhee Lee, Pavlos Msaouel, Yong Zang

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS
  • NIH HHS
  • National Institutes of Health
  • National Cancer Institute

Zitieren

APA

Zhao, S., Thall, P. F., Yuan, Y., Lee, J., Msaouel, P., & Zang, Y. (2025). Precision generalized phase I-II designs. Biometrics. https://doi.org/10.1093/biomtc/ujaf043

Vancouver

Zhao S, Thall PF, Yuan Y, Lee J, Msaouel P, Zang Y. Precision generalized phase I-II designs. Biometrics. 2025. doi:10.1093/biomtc/ujaf043

BibTeX
@article{Zhao2025,
  author = {Zhao, Saijun and Thall, Peter F and Yuan, Ying and Lee, Juhee and Msaouel, Pavlos and Zang, Yong},
  title = {Precision generalized phase I-II designs},
  journal = {Biometrics},
  year = {2025},
  doi = {10.1093/biomtc/ujaf043}
}
Kostenlos starten →